Navigation Links
Life Science Alley: R&D Makes German Medical Technologies Top in Europe
Date:12/8/2008

BERLIN, December 8 /PRNewswire/ -- Germany is Europe's largest market for medical devices. Total industry revenue in 2007 amounted to EUR 17.3 billion - a nearly 7 percent increase on 2006 figures. Investors looking to enter the German and European markets can learn about Germany at Life Science Alley, the largest convention of life science industry professionals in the American Midwest. The conference takes place December 10, 2008 in Minneapolis, Minnesota.

Germany's research landscape is making its medical technologies some of the most renowned and trusted worldwide. The country's advanced R&D network ensures that both patients and practitioners have access to the latest medical technologies.

Currently German medical technology companies spend about 9 percent of sales revenue on R&D. As a result, products under three years old account for 32 percent of industry revenue in Germany. Furthermore, Germany is number two in the world in patent applications in medical technologies.

Demographic developments suggest that Germany will remain strong in medical technologies in coming years. By 2015 it is expected that nearly one fifth of Germany's population will be over age 65, increasing the need for advanced medical technologies and health care.

Existing clusters of manufacturers, research institutes, and clinics allow companies of all sizes the chance to use Germany's investment conditions to maximize earnings quickly and efficiently. The availability of investment incentives as well as R&D and labor incentives also makes the country an attractive investment location.

Invest in Germany is the inward investment promotion agency of the Federal Republic of Germany. It provides investors with comprehensive support from site selection to the implementation of investment decisions. It can be found at booth 301 at Life Science Alley.

    Media Contact:
    Eva Henkel
    Phone: +49-30-200099-173
    Fax:   +49-30-200099-111
    Email: henkel@invest-in-germany.com



'/>"/>
SOURCE Invest in Germany GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 Research and ... Biology: Global Markets" report to their offering. ... ... genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, ... assembly, genome editing, bioinformatics and specialty media) and enabled ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... , Feb. 16, 2017 UCHealth ( ... utilize LungDirect for pulmonary nodule patient management. In addition ... or a spot on the lung, UCHealth looks to ... manual data entry. Stephanie Brown, RN ... my nodule patients with an Excel spreadsheet, which was ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):